Review—Recent Advances in Electrochemical Detection of Prostate Specific Antigen (PSA) in Clinically-Relevant Samples

Traynor, Sarah M.; Pandey, Richa; Maclachlan, Roderick; Hosseini, Amin; Didar, Tohid F.; Li, Feng; Soleymani, Leyla

doi:10.1149/1945-7111/ab69fd

Cited by 46 publications

(31 citation statements)

References 116 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are clinically approved immunoassays for PSA detection [ 190 , 191 ] and numerous electrochemical aptasensors aiming at inexpensive and robust ways of PSA electroanalysis have been reported and intensively overviewed [ 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 ]. Here, we update only few very recent reports.…”

Section: Electrochemical Assays For Cancer Biomarkersmentioning

confidence: 99%

Design Strategies for Electrochemical Aptasensors for Cancer Diagnostic Devices

Malecka

Mikuła

Ferapontova

2021

Sensors

View full text Add to dashboard Cite

Improved outcomes for many types of cancer achieved during recent years is due, among other factors, to the earlier detection of tumours and the greater availability of screening tests. With this, non-invasive, fast and accurate diagnostic devices for cancer diagnosis strongly improve the quality of healthcare by delivering screening results in the most cost-effective and safe way. Biosensors for cancer diagnostics exploiting aptamers offer several important advantages over traditional antibodies-based assays, such as the in-vitro aptamer production, their inexpensive and easy chemical synthesis and modification, and excellent thermal stability. On the other hand, electrochemical biosensing approaches allow sensitive, accurate and inexpensive way of sensing, due to the rapid detection with lower costs, smaller equipment size and lower power requirements. This review presents an up-to-date assessment of the recent design strategies and analytical performance of the electrochemical aptamer-based biosensors for cancer diagnosis and their future perspectives in cancer diagnostics.

show abstract

Section: Electrochemical Assays For Cancer Biomarkersmentioning

confidence: 99%

Design Strategies for Electrochemical Aptasensors for Cancer Diagnostic Devices

Malecka

Mikuła

Ferapontova

2021

Sensors

View full text Add to dashboard Cite

show abstract

“…At low frequencies, Nyquist plots may show straight lines with a slope of 45°. This is characteristic for diffusion limited processes and described by the Warburg impedance [ 8 , 9 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Microfluidic Impedance Biosensor Chips Using Sensing Layers Based on DNA-Based Self-Assembled Monolayers for Label-Free Detection of Proteins

et al. 2021

View full text Add to dashboard Cite

A microfluidic chip for electrochemical impedance spectroscopy (EIS) is presented as bio-sensor for label-free detection of proteins by using the example of cardiac troponin I. Troponin I is one of the most specific diagnostic serum biomarkers for myocardial infarction. The microfluidic impedance biosensor chip presented here consists of a microscope glass slide serving as base plate, sputtered electrodes, and a polydimethylsiloxane (PDMS) microchannel. Electrode functionalization protocols were developed considering a possible charge transfer through the sensing layer, in addition to analyte-specific binding by corresponding antibodies and reduction of nonspecific protein adsorption to prevent false-positive signals. Reagents tested for self-assembled monolayers (SAMs) on gold electrodes included thiolated hydrocarbons and thiolated oligonucleotides, where SAMs based on the latter showed a better performance. The corresponding antibody was covalently coupled on the SAM using carbodiimide chemistry. Sampling and measurement took only a few minutes. Application of a human serum albumin (HSA) sample, 1000 ng/mL, led to negligible impedance changes, while application of a troponin I sample, 1 ng/mL, led to a significant shift in the Nyquist plot. The results are promising regarding specific detection of clinically relevant concentrations of biomarkers, such as cardiac markers, with the newly developed microfluidic impedance biosensor chip.

show abstract

“…In many cases, the slow-growing type does not kill the patient, but dies with the patient, while the aggressive type can be fast-growing and fatal. Many patients with PSA levels above 4 ng/mL are advised for further examination which involves a DRE and prostate tissue biopsy [Farolfi et al, 2018;Traynor et al, 2020]. Currently, treatment modalities include surgical options such as radical prostatectomy, endocrine therapy like orchidectomy, and others such as radiotherapy, brachytherapy and chemotherapy [Ye et al, 2020].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Assessment of Diet-Derived Phytochemicals on PSA Secretion

Onuoha¹,

Ikimi²

2021

African Journal of Biology and Medical Research

View full text Add to dashboard Cite

Prostate cancer (PCa) is increasingly a global public health burden. The prostate specific antigen (PSA) is the major biomarker for diagnosing and managing PCa. Due to the importance of PSA as a biomarker and as a downstream product of the androgen receptor (AR), it was imperative to expose LNCaP cells to selective diet-derived phytochemicals and investigate the effect on PSA protein secretion. The phytochemicals: Curcumin, 3,3’-Diindolylmethane (DIM) and Epigallcatechin-3-gallate (EGCG) were utilised singly and in paired combinations as in vitro treatments. The ELISA technique was utilised to assess secreted PSA levels. Results obtained indicated that DIM posed inhibitory effects to PSA production and secretion. Uniquely, DIM lowered PSA levels significantly when compared to curcumin and EGCG. This finding corroborates with previous reports where DIM was observed to inhibit AR protein expression. It is suggestive that DIM targets the androgen receptor and its downstream pathway that produces PSA. In conclusion, DIM may hold overwhelming potential chemoprevention and management of PCa, and can be harnessed for enhanced clinical applications.

show abstract

Review—Recent Advances in Electrochemical Detection of Prostate Specific Antigen (PSA) in Clinically-Relevant Samples

Cited by 46 publications

References 116 publications

Design Strategies for Electrochemical Aptasensors for Cancer Diagnostic Devices

Design Strategies for Electrochemical Aptasensors for Cancer Diagnostic Devices

Microfluidic Impedance Biosensor Chips Using Sensing Layers Based on DNA-Based Self-Assembled Monolayers for Label-Free Detection of Proteins

In Vitro Assessment of Diet-Derived Phytochemicals on PSA Secretion

Contact Info

Product

Resources

About